RESUMO
The ISOLPHARM (ISOL technique for radioPHARMaceuticals) project is dedicated to the development of high purity radiopharmaceuticals exploiting the radionuclides producible with the future Selective Production of Exotic Species (SPES) Isotope Separation On-Line (ISOL) facility at the Legnaro National Laboratories of the Italian National Institute for Nuclear Physics (INFN-LNL). At SPES, a proton beam (up to 70 MeV) extracted from a cyclotron will directly impinge a primary target, where the produced isotopes are released thanks to the high working temperatures (2000 °C), ionized, extracted and accelerated, and finally, after mass separation, only the desired nuclei are collected on a secondary target, free from isotopic contaminants that decrease their specific activity. A case study for such project is the evaluation of the feasibility of the ISOL production of 64Cu and 67Cu using a zirconium germanide target, currently under development. The producible activities of 64Cu and 67Cu were calculated by means of the Monte Carlo code FLUKA, whereas dedicated off-line tests with stable beams were performed at LNL to evaluate the capability to ionize and recover isotopically pure copper.
Assuntos
Radioisótopos de Cobre/isolamento & purificação , Compostos Radiofarmacêuticos/isolamento & purificação , Ciclotrons , Temperatura Alta , Método de Monte Carlo , Radioquímica/instrumentaçãoRESUMO
In the framework of ISOL (isotope separation on-line) facilities, porous carbides are among the most employed target materials for the production of radioactive ion beams for research. As foreseen by the ISOL technique, a production target is impinged by an energetic particle beam, inducing nuclear reactions from such an interaction. The resulting radionuclides are subsequently released, thanks to the high target working temperature (1600-2000 °C); ionized; and extracted into a beam. Since the target microstructure and porosity play a fundamental role in the radionuclide release efficiency, custom-made target materials are often specifically produced, resulting in unknown thermal and structural properties. Considering that such targets might undergo intense thermal stresses during operation, a thermal and structural characterization is necessary to avoid target failure under irradiation. In the presented work, a custom-made porous titanium carbide that was specifically designed for application as an ISOL target was produced and characterized. The thermal characterization was focused on the evaluation of the material emissivity and thermal conductivity in the 600-1400 °C temperature range. For the estimation of a reference material tensile stress limit, the virtual thermoelastic parameter approach was adopted. In particular, for the aforementioned temperature range, an emissivity between 0.7 and 0.8 was measured, whereas a thermal conductivity between 8 and 10 W/mK was estimated.
RESUMO
In the facilities for the production of Radioactive Ion Beams (RIBs) according to the Isotope Separation On-Line (ISOL) technique, a production target is typically impinged by a high-power primary beam, generating radioactive isotopes for basic research and technological applications. With the aim to guarantee an efficient extraction of the aforementioned isotopes, the production target must work in a high vacuum environment, at temperatures that are usually between 1600 °C and 2200 °C. Its main components are often characterized by intense temperature gradients and consequently by severe thermal stresses. Carbides are widely used for target manufacturing, and in this work a specific method for their thermal and mechanical characterization is presented and discussed. It is based on the comparison between experimental measurements and numerical simulations, with the introduction of the novel Virtual Thermoelastic Parameters approach for the structural verification procedure. High-performance silicon carbides (SiC) are taken as a reference to describe the method. Measured emissivity and thermal conductivity data are presented and discussed, together with the experimental estimation of material limitations for both temperature and stress fields. The aforementioned results can be promptly used for the design process of high-power ISOL targets.
RESUMO
Research in the field of radiopharmaceuticals is increasingly promoted by the widespread and growing interest in applying nuclear medicine procedures in both disease diagnosis and treatment. The production of radionuclides of medical interest is however a challenging issue. Along with the conventional techniques other innovative approaches are being investigated and, among those, the ISOLPHARM project is being developed at INFN-LNL (Istituto Nazionale di Fisica Nucleare - Laboratori Nazionali di Legnaro). Such technique foresees the employment of the SPES ISOL facility to produce isobarically pure Radioactive Ion Beams (RIBs), obtained thanks to electromagnetic mass separation and collected on appropriate substrates. The latter are successively recovered and dissolved, allowing thus the chemical separation and harvesting of the nuclides of interest, free from any isotopic contaminant. Although ISOLPHARM can be potentially employed for most of the routinely used medical radioisotopes, its innovation potential is better expressed considering its capability to provide carrier free unconventional nuclides, difficult to produce with state-of-art techniques, such as 111Ag, a ß- emitter potentially interesting for therapeutic applications. Thus, in the framework of ISOLPHARM, INFN supported a two-years experiment, called ISOLPHARM_Ag, aimed at evaluating the feasibility of the production of a111Ag labelled radiopharmaceutical. The ISOL production yields are estimated by computing intensive Monte Carlo codes, that require an appropriate custom Information Technology infrastructure. The presented work is focused on the first part of the production chain including the capability to extract, ionize, and collect stable Ag beams with SPES technologies. MC calculations were used to estimate the expected 111Ag in-target yields, whereas experiments with stable Ag were performed to test the ionization, transport and collection of Ag beams.
Assuntos
Compostos Radiofarmacêuticos/síntese química , Prata/química , Desenvolvimento de Medicamentos , Método de Monte Carlo , Aceleradores de PartículasRESUMO
Abstract At INFN-LNL (Istituto Nazionale di Fisica Nucleare- Laboratori Nazionali di Legnaro) SPES (Selective Production of Exotic Species), a new facility for the production of radioactive ion beams is being constructed at INFN-LNL (Istituto Nazionale di Fisica Nucleare - Laboratori Nazionali di Legnaro). Radioactive ion beams of neutron-rich nuclei with high purity, in the range of mass between 80 and 160 amu, will be produced by nuclear reactions induced by 40 MeV protons from a cyclotron. The goal of the ISOLPHARM project is to provide a feasibility study for an innovative technology for the production of extremely very high specific activity beta emitting radionuclides as radiopharmaceutical precursors. The ISOL method, adopted in the ISOLPHARM project (a branch of the SPES project), gives the possibility of obtaining pure isobaric beams. In this way, no isotopic contaminations will be present in the beam and afterwards in a proper trapping substrate. The ground-breaking idea of the ISOLPHARM method was granted an International patent (INFN).
Resumen En INFN-LNL (Istituto Nazionale di Fisica Nucleare - Laboratori Nazionali di Legnaro) SPES (Producción selectiva de especies exóticas), se está construyendo una nueva instalación para la producción de haces de iones radiactivos en INFN-LNL (Istituto Nazionale di Fisica Nucleare - Laboratori Nazionali di Legnaro). Se producirán haces de iones radiactivos de núcleos ricos en neutrones con alta pureza, en el rango de masa entre 80 y 160 amu, por reacciones nucleares inducidas por protones de 40 MeV de un ciclotrón. El objetivo del proyecto ISOLPHARM es proporcionar un estudio de viabilidad para una tecnología innovadora para la producción de radionúclidos emisores de beta de actividad específica extremadamente alta como precursores radiofarmacéuticos. El método ISOL, adoptado en el proyecto ISOLPHARM (una rama del proyecto SPES), ofrece la posibilidad de obtener haces isobáricos puros. De esta manera, no habrá contaminaciones isotópicas en el haz y luego en un sustrato de atrapamiento adecuado. La idea pionera del método ISOLPHARM recibió una patente internacional (INFN).